Home / Companies / ESSA Pharma Inc. / 3 Oct 2025
ESSA Pharma Inc.: meeting of 3 Oct 2025
Votes reported on Form N-PX, item by item
29 Form N-PX filers reported votes at the ESSA Pharma Inc. meeting of 3 Oct 2025. Their records fall into 2 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
SECTION 14A SAY-ON-PAY VOTESIssuer
Advisory vote on executive pay (say-on-pay)
30 vote records from 28 filers. 2 of the 24 filers that marked the item either way voted against management. 4 filers reported this item without a management mark.
EXTRAORDINARY TRANSACTIONSIssuer
EXTRAORDINARY TRANSACTIONS: management items
Management items in this category are shown together; filers word and number them differently.
9 vote records from 3 filers. 0 of the 3 filers that marked the item either way voted against management.
How the largest families voted
| Family | 1. Say-on-pay |
|---|---|
| BlackRock and iShares | For |
| Fidelity | For |
| American Century | Against * |
| Goldman Sachs | For |
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the ESSA Pharma Inc. meeting?
29 Form N-PX filers reported votes at the meeting of 3 Oct 2025. On say-on-pay, 2 of 24 voted against management (8.3%). The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by ESSA Pharma Inc. on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for ESSA Pharma Inc.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing ESSA Pharma Inc. with a meeting date within three days of 3 Oct 2025. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.